Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer
Authors:
- Nicolas CaptierNCNicolas Captier
- Marvin LerousseauMLMarvin Lerousseau
- Fanny OrlhacFOFanny Orlhac
- Narinée Hovhannisyan-BaghdasarianNHNarinée Hovhannisyan-Baghdasarian
- Marie LuporsiMLMarie Luporsi
- Erwin WoffEWErwin Woff
- Sarah LaghaSLSarah Lagha
- Christine LonjouCLChristine Lonjou
- Clément BeaulatonCBClément Beaulaton
- Andrei ZinovyevAndrei Zinovyev
- Hélène SalmonHSHélène Salmon
Top Cited Papers
Open Access
- 12 January 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Abstract
Immunotherapy is improving the survival of patients with metastatic non-small cell lung cancer (NSCLC), yet reliable biomarkers are needed to identify responders prospectively and optimize patient care. In this study, we explore the benefits of multimodal approaches to predict immunotherapy outcome using multiple machine learning algorithms and integration strategies. We analyze baseline multimodal data from a cohort of 317 metastatic NSCLC patients treated with first-line immunotherapy, including positron emission tomography images, digitized pathological slides, bulk transcriptomic profiles, and clinical information. Testing multiple integration strategies, most of them yield multimodal models surpassing both the best unimodal models and established univariate biomarkers, such as PD-L1 expression. Additionally, several multimodal combinations demonstrate improved patient risk stratification compared to models built with routine clinical features only. Our study thus provides evidence of the superiority of multimodal over unimodal approaches, advocating for the collection of large multimodal NSCLC datasets to develop and validate robust and powerful immunotherapy biomarkers.Keywords
All Related Versions
Funding Information
- Fondation ARC pour la Recherche sur le Cancer (SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy, SIGN’IT 2020—Signatures in Immunotherapy)
- Agence Nationale de la Recherche (ANR-19-P3IA-0001, ANR-19-P3IA-0001, ANR-19-P3IA-0001)
This publication has 49 references indexed in Scilit:
- VarDict: a novel and versatile variant caller for next-generation sequencing in cancer researchNucleic Acids Research, 2016
- Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF InhibitionImmunity, 2016
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic CellsCancer Discovery, 2016
- Biomarker: Predictive or Prognostic?Journal of Clinical Oncology, 2015
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityCancer Cell, 2014
- Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T CellsCancer Research, 2014
- On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival dataStatistics in Medicine, 2011
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03European Journal of Cancer, 2009
- A permutation test sensitive to differences in areas for comparing ROC curves from a paired designStatistics in Medicine, 2005